Acrivon Therapeutics Inc (ACRV)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.73-1.70%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Acrivon Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	583,000
EPS	—	-0.434
Annual ending 2026-12-31
Revenue	—	1.5M
EPS	—	-1.85
Annual ending 2027-12-31
Revenue	—	166,286
EPS	—	-1.656

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash reserves to fund operations into Q2 2027	The company has about $119 million cash to fund operations into Q2 2027.	Intact	cash reserves fall below $118.6 million before Q2 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
ACR-368 Phase 2b trial response rate	Acrivon is making progress in cancer drug trials with 44% response rate.	Intact	ORR falls below 39% overall or below 44% in ≤2 prior therapy patients	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating losses and cash burn control	Operating losses are improving from -$25.1 million to -$19.9 million.	Intact	operating loss worsens beyond -$19.9 million or cash burn beyond -$12.3 million	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Operating losses improved modestly from -$21.0 million in 2025-Q2 to -$18.0 million in 2026-Q2, driven by reduced R&D and G&A expenses. Cash from operations remains negative, reflecting ongoing burn, but expense control efforts show limited progress consistent with management's statements. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.66

$-1.95 → $-1.66 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.95	$166,286	6 / 5
2026-07-25	$-1.95	$166,286	6 / 5
2026-07-26	$-1.95	$166,286	6 / 5
2026-07-27	$-1.95	$166,286	6 / 5
2026-07-28	$-1.95	$166,286	6 / 5
2026-07-29	$-1.95	$145,500	7 / 8
2026-07-30	$-1.95	$145,500	7 / 8
2026-07-31	$-1.95	$145,500	7 / 8
2026-08-01	$-1.95	$145,500	7 / 8
2026-08-02	$-1.95	$145,500	7 / 8
2026-08-03	$-1.95	$145,500	7 / 8
2026-08-04	$-1.95	$145,500	7 / 8
2026-08-05	$-1.95	$145,500	7 / 8
2026-08-06	$-1.95	$145,500	7 / 8
2026-08-07	$-1.95	$166,286	6 / 5
2026-08-08	$-1.95	$145,500	7 / 8
2026-08-09	$-1.95	$145,500	7 / 8
2026-08-10	$-1.95	$145,500	7 / 8
2026-08-11	$-1.95	$145,500	7 / 8
2026-08-12	$-1.95	$145,500	7 / 8
2026-08-13	$-1.95	$145,500	7 / 8
2026-08-14	$-1.95	$166,286	6 / 5
2026-08-15	$-1.95	$166,286	6 / 5
2026-08-16	$-1.95	$166,286	6 / 5
2026-08-17	$-1.95	$166,286	6 / 5
2026-08-18	$-1.95	$166,286	6 / 5
2026-08-19	$-1.95	$166,286	6 / 5
2026-08-20	$-1.73	$166,286	6 / 5
2026-08-21	$-1.73	$166,286	6 / 5
2026-08-22	$-1.73	$166,286	6 / 5
2026-08-23	$-1.79	$166,286	5 / 5
2026-08-24	$-1.79	$166,286	5 / 5
2026-08-25	$-1.79	$166,286	5 / 5
2026-08-26	$-1.79	$166,286	5 / 5
2026-08-27	$-1.79	$166,286	5 / 5
2026-08-28	$-1.79	$166,286	5 / 5
2026-08-29	$-1.79	$166,286	5 / 5
2026-08-30	$-1.79	$166,286	5 / 5
2026-08-31	$-1.79	$166,286	5 / 5
2026-09-01	$-1.79	$166,286	5 / 5
2026-09-02	$-1.79	$166,286	5 / 5
2026-09-03	$-1.79	$166,286	5 / 5
2026-09-04	$-1.79	$166,286	5 / 5
2026-09-05	$-1.79	$166,286	5 / 5
2026-09-06	$-1.79	$166,286	5 / 5
2026-09-07	$-1.79	$166,286	5 / 5
2026-09-08	$-1.79	$166,286	5 / 5
2026-09-09	$-1.79	$166,286	5 / 5
2026-09-10	$-1.79	$166,286	5 / 5
2026-09-11	$-1.79	$166,286	5 / 5
2026-09-12	$-1.79	$166,286	5 / 5
2026-09-13	$-1.79	$166,286	5 / 5
2026-09-14	$-1.79	$166,286	5 / 5
2026-09-15	$-1.79	$166,286	5 / 5
2026-09-16	$-1.79	$166,286	5 / 5
2026-09-17	$-1.79	$166,286	5 / 5
2026-09-18	$-1.79	$166,286	5 / 5
2026-09-19	$-1.79	$166,286	5 / 5
2026-09-20	$-1.79	$166,286	5 / 5
2026-09-21	$-1.79	$166,286	5 / 5
2026-09-22	$-1.79	$166,286	5 / 5
2026-09-23	$-1.79	$166,286	5 / 5
2026-09-24	$-1.79	$166,286	5 / 5
2026-09-25	$-1.66	$166,286	5 / 5
2026-09-26	$-1.66	$166,286	5 / 5
2026-09-27	$-1.66	$166,286	5 / 5
2026-09-28	$-1.66	$166,286	5 / 5
2026-09-29	$-1.66	$166,286	5 / 5
2026-09-30	$-1.66	$166,286	5 / 5
2026-10-01	$-1.66	$166,286	5 / 5
2026-10-02	$-1.66	$166,286	5 / 5
2026-10-03	$-1.66	$166,286	5 / 5
2026-10-04	$-1.66	$166,286	5 / 5
2026-10-05	$-1.66	$166,286	5 / 5
2026-10-06	$-1.66	$166,286	5 / 5
2026-10-07	$-1.66	$166,286	5 / 5
2026-10-08	$-1.66	$166,286	5 / 5
2026-10-09	$-1.66	$166,286	5 / 5
2026-10-10	$-1.66	$166,286	5 / 5
2026-10-11	$-1.66	$166,286	5 / 5
2026-10-12	$-1.66	$166,286	5 / 5
2026-10-13	$-1.66	$166,286	5 / 5
2026-10-14	$-1.66	$166,286	5 / 5
2026-10-15	$-1.66	$166,286	5 / 5
2026-10-16	$-1.66	$166,286	5 / 5
2026-10-17	$-1.66	$166,286	5 / 5
2026-10-18	$-1.66	$166,286	5 / 5
2026-10-19	$-1.66	$166,286	5 / 5
2026-10-20	$-1.66	$166,286	5 / 5
2026-10-21	$-1.66	$166,286	5 / 5
2026-10-22	$-1.66	$166,286	5 / 5
2026-10-23	$-1.66	$166,286	5 / 5
2026-10-24	$-1.66	$166,286	5 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	8	0	0
2026-06-01	8	0	0
2026-07-01	8	0	0
2026-08-01	8	0	0
2026-09-01	7	0	0
2026-10-01	7	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash reserves to fund operations into Q2 2027Direct metric needs a verified mapping
ACR-368 Phase 2b trial response rateDirect metric needs a verified mapping
Operating losses and cash burn controlDirect metric needs a verified mapping

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-57.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Acrivon Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The multi-year thesis is in a watch state: management is advancing two programs, but losses continue and overall evidence confidence is low.

What's priced into Acrivon Therapeutics Inc

The snapshot gives no valuation multiple or peer comparison, so whether ACRV is cheap, fair, or expensive is unclear. The available evidence does not show what clinical success or continued cash needs the market already assumes.

What the fundamentals likely do

Near term, continued operating losses and negative operating cash flow remain central, though operating losses improved modestly by 2026-Q2. Management says current cash is expected to fund operations into late 2027, while the planned ACR-368 interim analysis is in the second half of 2026; execution evidence is mixed. The next report carries elevated miss risk, and a guidance cut is a stated downside trigger.

What Acrivon Therapeutics Inc hinges on

Over the multi-year view, the thesis hinges on progress in the registrational Phase 2b study of ACR-368 and the randomized dose expansion of ACR-2316, alongside control of cash burn. Near term, weaker jobs data could weigh on cyclical shares, while strong results and guidance from healthcare bellwethers could support sector momentum; neither resolves ACRV's clinical and funding risks.